Redmile Group initiated a new 700,000-share ($5.1M) position in Eupraxia Pharmaceuticals, flagging the healthcare crossover fund's interest ahead of the Phase 2 readout for EP-104GI in Eosinophilic Esophagitis, expected by end of 2026. EP-104GI is a locally-delivered, extended-release fluticasone formulation designed to provide durable mucosal coverage in EoE, an indication with validated commercial precedent (dupilumab, budesonide oral suspension) but room for differentiated delivery approaches.

Unlock full AI analysis — 14-day free trial

2 quarters

Position Trend

May 15, 2026

$5.1M

1 fund

Aug 14, 2026

$5.8M

2 funds

+15% total institutional value over 2 quarters

Short Interest

High short interestSI rising 10 periods (+137.8%)

Short Shares

6.04M

Change

+2.1%

Days to Cover

18.5

Settlement

Aug 14, 2026

Short interest over 11 periods

Catalysts

Phase 2Q2 2023EP-104IAR 25 mgOsteoarthritis, KneeNCT04120402

Phase 2Q4 2026EP-104GIEosinophilic EsophagitisNCT05608681

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

OrbiMed AdvisorsNEW POSITIONAug 14, 2026

Start free trialfor share counts, dollar values & AI analysis

2 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

ADCT2 funds SYK2 funds PGNY2 funds AKRO2 funds ALXO2 funds FOLD2 funds APLS2 funds BSX2 funds

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer